Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

100 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Systemic lupus erythematosus: an update on current pharmacotherapy and future directions.
Touma Z, Urowitz MB, Gladman DD. Touma Z, et al. Expert Opin Biol Ther. 2013 May;13(5):723-37. doi: 10.1517/14712598.2013.764411. Epub 2013 Jan 23. Expert Opin Biol Ther. 2013. PMID: 23339281 Review.
SLEDAI-2K for a 30-day window.
Touma Z, Urowitz MB, Gladman DD. Touma Z, et al. Lupus. 2010 Jan;19(1):49-51. doi: 10.1177/0961203309346505. Epub 2009 Nov 12. Lupus. 2010. PMID: 19910390
Burden of autoantibodies and association with disease activity and damage in systemic lupus erythematosus.
Touma Z, Gladman DD, Tulloch-Reid D, Toloza SM, Ibañez D, Fortin PR, Urowitz MB. Touma Z, et al. Clin Exp Rheumatol. 2010 Jul-Aug;28(4):525-31. Epub 2010 Aug 30. Clin Exp Rheumatol. 2010. PMID: 20659409
Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis.
Touma Z, Gladman DD, Urowitz MB, Beyene J, Uleryk EM, Shah PS. Touma Z, et al. J Rheumatol. 2011 Jan;38(1):69-78. doi: 10.3899/jrheum.100130. Epub 2010 Oct 15. J Rheumatol. 2011. PMID: 20952473 Review.
Optimal frequency of visits for patients with systemic lupus erythematosus to measure disease activity over time.
Ibañez D, Gladman DD, Touma Z, Nikpour M, Urowitz MB. Ibañez D, et al. Among authors: touma z. J Rheumatol. 2011 Jan;38(1):60-3. doi: 10.3899/jrheum.100575. Epub 2010 Nov 15. J Rheumatol. 2011. PMID: 21078718
Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50.
Touma Z, Gladman DD, Ibañez D, Urowitz MB. Touma Z, et al. J Rheumatol. 2011 Feb;38(2):275-84. doi: 10.3899/jrheum.100724. Epub 2010 Dec 1. J Rheumatol. 2011. PMID: 21123323
SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation.
Touma Z, Urowitz MB, Ibañez D, Gladman DD. Touma Z, et al. Lupus. 2011 Jan;20(1):67-70. doi: 10.1177/0961203310385163. Lupus. 2011. PMID: 21233149
Systemic lupus erythematosus disease activity index 2000 responder index-50: a reliable index for measuring improvement in disease activity.
Touma Z, Urowitz MB, Fortin PR, Landolt C, Toloza SM, Riddell C, Chandran V, Eder L, Ghanem A, Ziouzina O, Taghavi-Zadeh S, Ibañez D, Gladman DD. Touma Z, et al. J Rheumatol. 2011 May;38(5):868-73. doi: 10.3899/jrheum.101080. Epub 2011 Feb 15. J Rheumatol. 2011. PMID: 21324961
Is there an advantage over SF-36 with a quality of life measure that is specific to systemic lupus erythematosus?
Touma Z, Gladman DD, Ibañez D, Urowitz MB. Touma Z, et al. J Rheumatol. 2011 Sep;38(9):1898-905. doi: 10.3899/jrheum.110007. Epub 2011 Jul 1. J Rheumatol. 2011. PMID: 21724700
Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index-50 enhances the ability of SLE Responder Index to identify responders in clinical trials.
Touma Z, Gladman DD, Ibañez D, Taghavi-Zadeh S, Urowitz MB. Touma Z, et al. J Rheumatol. 2011 Nov;38(11):2395-9. doi: 10.3899/jrheum.110550. Epub 2011 Sep 1. J Rheumatol. 2011. PMID: 21885488
100 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback